NVAX Stock Overview
A biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Novavax, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.81 |
| 52 Week High | US$23.86 |
| 52 Week Low | US$3.53 |
| Beta | 2.06 |
| 1 Month Change | 1.26% |
| 3 Month Change | -11.90% |
| 1 Year Change | 106.81% |
| 3 Year Change | -88.59% |
| 5 Year Change | 22.87% |
| Change since IPO | -88.99% |
Recent News & Updates
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
Jan 16Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth
Dec 17
Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target
Nov 15Recent updates
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade)
Jan 16Novavax, Inc. (NASDAQ:NVAX) Shares Fly 26% But Investors Aren't Buying For Growth
Dec 17Novavax, Inc. (NASDAQ:NVAX) Just Reported, And Analysts Assigned A US$16.67 Price Target
Nov 15Novavax Q3 Earnings Disappoint, But A Turnaround May Be Underway
Nov 13Novavax, Inc.'s (NASDAQ:NVAX) 35% Dip In Price Shows Sentiment Is Matching Revenues
Nov 01Novavax Q3 Earnings A Week Away - Time To Accept A New Reality
Oct 31Novavax's Future Hinges On Sanofi Deal And Upcoming Milestones
Sep 01Novavax, Inc.'s (NASDAQ:NVAX) Shares Lagging The Industry But So Is The Business
Aug 14Novavax: Staying Long Despite Coming Up Short In Q2
Aug 13Novavax Ahead Of Q2 Earnings - Picking Apart The Sanofi Deal
Jul 26Novavax: New Chapter, Questions Remain
Jun 20Novavax, Inc. (NASDAQ:NVAX) Surges 206% Yet Its Low P/S Is No Reason For Excitement
May 14Novavax, Inc. (NASDAQ:NVAX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 13Novavax Q1 2024 Earnings Preview: Success In New Commercial COVID Markets Unlikely
May 07Novavax: Another Day Older And Deeper In
Mar 02Novavax, Inc.'s (NASDAQ:NVAX) Shares Bounce 35% But Its Business Still Trails The Industry
Mar 02Earnings Update: Here's Why Analysts Just Lifted Their Novavax, Inc. (NASDAQ:NVAX) Price Target To US$22.00
Mar 01Novavax Q4 Earnings Preview: Settlement With Gavi Doesn't Solve Problems
Feb 23Investors Don't See Light At End Of Novavax, Inc.'s (NASDAQ:NVAX) Tunnel
Sep 06Shareholder Returns
| NVAX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.6% | 3.6% | 3.8% |
| 1Y | 106.8% | -6.1% | 24.4% |
Return vs Industry: NVAX exceeded the US Biotechs industry which returned -6.1% over the past year.
Return vs Market: NVAX exceeded the US Market which returned 24.4% over the past year.
Price Volatility
| NVAX volatility | |
|---|---|
| NVAX Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NVAX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NVAX's weekly volatility has decreased from 20% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,543 | John Jacobs | global.novavax.com |
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination.
Novavax, Inc. Fundamentals Summary
| NVAX fundamental statistics | |
|---|---|
| Market cap | US$1.35b |
| Earnings (TTM) | -US$284.86m |
| Revenue (TTM) | US$885.19m |
1.6x
P/S Ratio-5.0x
P/E RatioIs NVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVAX income statement (TTM) | |
|---|---|
| Revenue | US$885.19m |
| Cost of Revenue | US$769.73m |
| Gross Profit | US$115.46m |
| Other Expenses | US$400.32m |
| Earnings | -US$284.86m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.78 |
| Gross Margin | 13.04% |
| Net Profit Margin | -32.18% |
| Debt/Equity Ratio | -32.2% |
How did NVAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 03:15 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novavax, Inc. is covered by 25 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| George Zavoico | B. Riley Securities, Inc. |